Kineta's adjuvants enhance efficiency of flu vaccine

Kineta Inc., a biotechnology company focused on the development of immune modulating drugs for infectious diseases, released new data on Thursday that shows its vaccine adjuvants are increasing the defense of influenza vaccines in animal models.

Kineta’s adjuvant system controls influenza infection by enhancing the antiviral cellular immune response and enhancing the production of functional antibodies. Adjuvants are molecules that are added to a vaccine in order to improve the body’s vaccine immune response.

Kineta’s small molecule adjuvant program is being developed for a highly pathogenic influenza vaccine virus to deliver antigen sparing and heterologous protection against diverse flu strains.

“Our vaccine adjuvants enhance the protection conferred by existing influenza vaccines as demonstrated in lethal mouse infection models and are also dose sparing and have the potential to strengthen the effectiveness of a variety of vaccines,” Chelsea Olsen, director of program management and virology at Kineta, said. “In addition, unlike conventional vaccine adjuvants, our host-directed small molecule compounds stimulate innate antiviral pathways, which results in a more specific response.”

Olsen presented the data in an oral presentation at the World Vaccine Congress during the Influenza and Respiratory segment.

The adjuvant system was discovered through Kineta’s proprietary AViid discovery platform, which is focused on the small molecules that activate the IRF-dependent immune pathways.

Organizations in this Story

Kineta, Inc.

Want to get notified whenever we write about Kineta, Inc. ?
Next time we write about Kineta, Inc., we'll email you a link to the story. You may edit your settings or unsubscribe at any time.